Comparison the Clinical Features of Newly Diagnosed Multiple Myeloma Patients According to CD23 Expression Status
Yıl: 2022 Cilt: 55 Sayı: 2 Sayfa Aralığı: 103 - 108 Metin Dili: İngilizce DOI: 10.5505/aot.2022.13008 İndeks Tarihi: 21-09-2022
Comparison the Clinical Features of Newly Diagnosed Multiple Myeloma Patients According to CD23 Expression Status
Öz: Introduction: The aim of the study was to evaluate the relationship between CD23 expression status and clinical features in multiple myeloma patients. Materials and methods: We retrospectively analyzed the data of 196 patients diagnosed with multiple myeloma in our institution between May 2010 and August 2018. Results: Compared to the CD23 negative group, in the CD23 positive group, the incidence of anemia was significantly lower, and the incidence of CD20 expression and the rate of R-ISS stage 1 patients was significantly higher. No similar association was found between R-ISS and other cell surface markers Discussion: In conclusion, clinical presentations of multiple myeloma patients with aberrant CD23 expression show some clinical differences from those without. The fact that MM patients with CD23 expression were clustered in the favorable prognostic group according to R-ISS drew attention to its prognostic value. For MM patients, the addition of CD23 to the routine flow cytometry panel may be considered. In this respect, examination of CD23 expression is required in a larger group of cases to assess its prognostic value in MM.
Anahtar Kelime: -
Öz: Giriş: Çalışmanın amacı, multipl miyelom hastalarında CD23 ekspresyon durumu ile hastaların klinik özellikleri arasındaki ilişkiyi değerlendirmektir. Gereç ve yöntemler: Mayıs 2010 ile Ağustos 2018 tarihleri arasında kurumumuzda multipl miyelom tanısı alan 196 hastanın verilerini retrospektif olarak inceledik. Bulgular: CD23 negatif gruba kıyasla CD23 pozitif gurupta anlamlı olarak anemi insidansı düşük, CD20 ekspresyon insidansı yüksek ve R-ISS evre 1 hasta oranı fazla gözlendi. R-ISS ile diğer hücre yüzey markırları arasında ise benzer bir ilişki bulunmadı. Tartışma: Sonuç olarak, aberran CD23 ekspresyonu olan multipl miyelom hastalarının klinik prezentasyonları bazı klinik farklılıklar göstermektedir. CD23 ekspresyonu olan MM hastalarının önemli kısmının R-ISS'ye göre iyi prognostik grupta yer alması CD23'ün prognostik değerine dikkat çekmiştir. MM hastaları için rutin akım sitometri paneline CD23'ün eklenmesi düşünülebilir. Bu açıdan, CD23'ün MM'deki prognostik değerini araştırmak için daha geniş bir vaka grubunda CD23 ekspresyonunun incelenmesi gereklidir.
Anahtar Kelime: Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
- 1. Paiva B, Almeida J, Pérez-Andrés M, Mateo G, López A, Rasillo A, Vídriales MB, López-Berges MC, Miguel JF OA. Utility of flow cytometry immunophenotyping in multiple myeloma and other clonal plasma cell-related disorders. Cytom B Clin Cytom 2010; 78:239–52.
- 2. Mateo G, Montalbán MA, Vidriales MB, Lahuerta JJ, Mateos MV, Gutiérrez N, et al. Prognostic value of immunophenotyping in multiple myeloma: a study by the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy. J Clin Oncol 2008; 26:2737–44.
- 3. Moreau P, Robillard N, Avet-Loiseau H, Pineau D, Morineau N, Milpied N, Harousseau JL BR. Patients with CD45 negative multiple myeloma receiving high-dose therapy have a shorter survival than those with CD45 positive multiple myeloma. Haematologica 2004; 89:547–51.
- 4. Gonsalves WI, Timm MM, Rajkumar SV, Morice WG, Dispenzieri A, Buadi FK, Lacy MQ, Dingli D, Leung N, Kapoor P, Kyle RA, Gertz MA KS. The prognostic significance of CD45 expression by clonal bone marrow plasma cells in patients with newly diagnosed multiple myeloma. Leuk Res 2016; 44:32–9.
- 5. Nowakowski GS, Witzig TE, Dingli D, Tracz MJ, Gertz MA, Lacy MQ, et al. Circulating plasma cells detected by flow cytometry as a predictor of survival in 302 patients with newly diagnosed multiple myeloma. Blood 2005; 106:2276–9.
- 6. Hibbert RG, Teriete P, Grundy GJ, Beavil RL, Reljic R, Holers VM, Hannan JP, Sutton BJ, Gould HJ MJ. The structure of human CD23 and its interactions with IgE and CD21. J Exp Med 2005; 202:751–60.
- 7. Barna G, Reiniger L, Tátrai P, Kopper L MA. The cut-off levels of CD23 expression in the differential diagnosis of MCL and CLL. Hematol Oncol 2008; 26:167–70.
- 8. Ruiz-Argüelles GJ SMJ. Cell surface markers in multiple myeloma. Mayo Clin Proc 1994; 69:684–90.
- 9. Walters M, Olteanu H, Van Tuinen P KS. CD23 expression in plasma cell myeloma is specific for abnormalities of chromosome 11, and is associated with primary plasma cell leukaemia in this cytogenetic sub-group. Br J Haematol 2010; 149:292–3.
- 10. Buonaccorsi JN, Kroft SH, Harrington AM, VanTuinen P OH. Clinicopathologic analysis of the impact of CD23 expression in plasma cell myeloma with t(11;14) (q13;q32). Ann Diagn Pathol 2011; 15:385–8.
- 11. Group. IMW. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol 2003; 121:749–57.
- 12. Palumbo A, Avet-Loiseau H, Oliva S, Lokhorst HM, Goldschmidt H, Rosinol L, et al. Revised International Staging System for Multiple Myeloma: A report from International Myeloma Working Group. J Clin Oncol 2015; 33: 2863-9.
| APA | Iltar U, salim o, Ulas T, Berker Karauzum S, Aydin C, Undar L (2022). Comparison the Clinical Features of Newly Diagnosed Multiple Myeloma Patients According to CD23 Expression Status. , 103 - 108. 10.5505/aot.2022.13008 |
| Chicago | Iltar Utku,salim ozan,Ulas Turgay,Berker Karauzum Sibel,Aydin Cigdem,Undar Levent Comparison the Clinical Features of Newly Diagnosed Multiple Myeloma Patients According to CD23 Expression Status. (2022): 103 - 108. 10.5505/aot.2022.13008 |
| MLA | Iltar Utku,salim ozan,Ulas Turgay,Berker Karauzum Sibel,Aydin Cigdem,Undar Levent Comparison the Clinical Features of Newly Diagnosed Multiple Myeloma Patients According to CD23 Expression Status. , 2022, ss.103 - 108. 10.5505/aot.2022.13008 |
| AMA | Iltar U,salim o,Ulas T,Berker Karauzum S,Aydin C,Undar L Comparison the Clinical Features of Newly Diagnosed Multiple Myeloma Patients According to CD23 Expression Status. . 2022; 103 - 108. 10.5505/aot.2022.13008 |
| Vancouver | Iltar U,salim o,Ulas T,Berker Karauzum S,Aydin C,Undar L Comparison the Clinical Features of Newly Diagnosed Multiple Myeloma Patients According to CD23 Expression Status. . 2022; 103 - 108. 10.5505/aot.2022.13008 |
| IEEE | Iltar U,salim o,Ulas T,Berker Karauzum S,Aydin C,Undar L "Comparison the Clinical Features of Newly Diagnosed Multiple Myeloma Patients According to CD23 Expression Status." , ss.103 - 108, 2022. 10.5505/aot.2022.13008 |
| ISNAD | Iltar, Utku vd. "Comparison the Clinical Features of Newly Diagnosed Multiple Myeloma Patients According to CD23 Expression Status". (2022), 103-108. https://doi.org/10.5505/aot.2022.13008 |
| APA | Iltar U, salim o, Ulas T, Berker Karauzum S, Aydin C, Undar L (2022). Comparison the Clinical Features of Newly Diagnosed Multiple Myeloma Patients According to CD23 Expression Status. ACTA ONCOLOGICA TURCICA, 55(2), 103 - 108. 10.5505/aot.2022.13008 |
| Chicago | Iltar Utku,salim ozan,Ulas Turgay,Berker Karauzum Sibel,Aydin Cigdem,Undar Levent Comparison the Clinical Features of Newly Diagnosed Multiple Myeloma Patients According to CD23 Expression Status. ACTA ONCOLOGICA TURCICA 55, no.2 (2022): 103 - 108. 10.5505/aot.2022.13008 |
| MLA | Iltar Utku,salim ozan,Ulas Turgay,Berker Karauzum Sibel,Aydin Cigdem,Undar Levent Comparison the Clinical Features of Newly Diagnosed Multiple Myeloma Patients According to CD23 Expression Status. ACTA ONCOLOGICA TURCICA, vol.55, no.2, 2022, ss.103 - 108. 10.5505/aot.2022.13008 |
| AMA | Iltar U,salim o,Ulas T,Berker Karauzum S,Aydin C,Undar L Comparison the Clinical Features of Newly Diagnosed Multiple Myeloma Patients According to CD23 Expression Status. ACTA ONCOLOGICA TURCICA. 2022; 55(2): 103 - 108. 10.5505/aot.2022.13008 |
| Vancouver | Iltar U,salim o,Ulas T,Berker Karauzum S,Aydin C,Undar L Comparison the Clinical Features of Newly Diagnosed Multiple Myeloma Patients According to CD23 Expression Status. ACTA ONCOLOGICA TURCICA. 2022; 55(2): 103 - 108. 10.5505/aot.2022.13008 |
| IEEE | Iltar U,salim o,Ulas T,Berker Karauzum S,Aydin C,Undar L "Comparison the Clinical Features of Newly Diagnosed Multiple Myeloma Patients According to CD23 Expression Status." ACTA ONCOLOGICA TURCICA, 55, ss.103 - 108, 2022. 10.5505/aot.2022.13008 |
| ISNAD | Iltar, Utku vd. "Comparison the Clinical Features of Newly Diagnosed Multiple Myeloma Patients According to CD23 Expression Status". ACTA ONCOLOGICA TURCICA 55/2 (2022), 103-108. https://doi.org/10.5505/aot.2022.13008 |
